Labiotech.eu’s Post

💰 Biotech's Top Investments This Week! 🚀 🇳🇱 uniQure | $345 million public offering | gene therapies | lead product for hemophilia B   🇺🇸 Crystalys Therapeutics | $205 million series A | URAT1 inhibitor | phase 3-ready in gout  🇺🇸 Immuneering Corporation | $200 million public offering + private placement | cancer therapies | phase 2a in pancreatic cancer 🇺🇸 MBX Biosciences, Inc. | $199.9 million public offering | peptide therapies | phase 2 in hypoparathyroidism 🇺🇸 Star Therapeutics | $125 million series D | antibody therapies | phase 3 in von Willebrand disease 🇺🇸 Sparrow Pharmaceuticals, Inc. | $95 million series B | targeted therapies | phase 2b in type 2 diabetes 🇺🇸 Seed Therapeutics | $30 million series A-3 | molecular glue degraders | lead asset for Ewing sarcoma and other RBM39-dependent cancers    🇫🇷 StemInov | €10.6 million ($12.4 million) | stem cell therapies | phase 1/2a ready in pneumonia complications 🇬🇧 Athernal Bio | £3.5 million ($4.7 million) financing | targeted immunotherapies | preclinical in high-risk clonal hematopoiesis 🇯🇵 Tres Alchemix | $4.4 million series A | AI drug design platform   🇺🇸 MAIA Biotechnology, Inc. | $2.25 million private placement | targeted immunotherapies | lead asset for NSCLC Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

💰 Biotech's Top Investments This Week! 🚀 🇺🇸 LB Pharmaceuticals Inc | $285 million IPO | neuropsychiatric disease therapeutics | phase 2 in acute schizophrenia 🇺🇸 Odyssey Therapeutics | $213 million series D | small molecules | phase 2 in ulcerative colitis and Crohn’s disease 🇺🇸 Oruka Therapeutics | $180 million private placement | antibody engineering | phase 2 in psoriasis 🇺🇸 Amylyx Pharmaceuticals | $175 million public offering | neurodegenerative disease therapeutics | phase 3 in post-bariatric hypoglycemia 🇨🇳 YolTech Therapeutics | $45 million in series B | gene editing | phase 1/2 familial hypercholesterolemia 🇨🇭 Basilea Pharmaceutica | $25 million funding | antifungals and antibiotics | phase 3 in candidemia   🇺🇸 Actuate Therapeutics, Inc. | $17.25 million public offering | cancer therapies | phase 2 in pancreatic cancer 🇺🇸 Citius Oncology, Inc. | $9 million registered direct offering and private placement | cancer therapies | recombinant fusion protein approved for cutaneous T-cell lymphoma Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

🚀 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗡𝗲𝘄𝘀 | 𝗦𝘁𝗲𝗽 𝗣𝗵𝗮𝗿𝗺𝗮 𝗥𝗮𝗶𝘀𝗲𝘀 €𝟯𝟴𝗠 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 🚀   We are proud to announce that our 𝗜𝗻𝗻𝗼𝗕𝗶𝗼 𝟮 portfolio company, Step Pharma, has successfully completed a €𝟯𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗻𝗴 𝗿𝗼𝘂𝗻𝗱!   This milestone will accelerate the clinical development of their lead asset, 𝗱𝗲𝗻𝗰𝗮𝘁𝗶𝘀𝘁𝗮𝘁, a first-in-class CTPS1 oral inhibitor, for the treatment of blood cancers, solid tumours and essential thrombocytemia. CTPS1 is a key component of the pyrimidine synthesis pathway for DNA synthesis and cell proliferation.   𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ▪️ €𝟯𝟴𝗠 𝗿𝗮𝗶𝘀𝗲𝗱 to fuel innovation in targeted cancer therapies ▪️ 𝗗𝗲𝗻𝗰𝗮𝘁𝗶𝘀𝘁𝗮𝘁: a first-in-class oral inhibitor of CTPS1 in clinical development ▪️ 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗶𝗻 𝗮 𝗽𝗿𝗼𝗱𝘂𝗰𝘁: three clinical programs (lymphoma, CTPS2-null solid tumours, essential thrombocythaemia) ▪️ 𝗡𝗲𝘄 𝗶𝗻𝘃𝗲𝘀𝘁𝗼𝗿: V-Bio Ventures leads the round, joined by historical investors Pontifax Venture Capital, Bpifrance Life Sciences Venture (InnoBio), Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures, and INSERM TRANSFERT INITIATIVE. ▪️ 𝗥𝗲𝗰𝗼𝗴𝗻𝗶𝘁𝗶𝗼𝗻: Dencatistat received orphan drug designation for T cell lymphoma (May 2025)   𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: Step Pharma’s approach — selectively inhibiting CTPS1 to kill cancer cells — could lead to a new highly selective, safe and effective treatment for several cancers.   Thibaut Roulon, Senior Investment Director at Bpifrance commented: "𝘞𝘪𝘵𝘩 𝘵𝘩𝘳𝘦𝘦 𝘪𝘯𝘥𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴 𝘣𝘦𝘪𝘯𝘨 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘵𝘦𝘴𝘵𝘦𝘥, 𝘋𝘦𝘯𝘤𝘢𝘵𝘪𝘴𝘵𝘢𝘵 𝘪𝘴 𝘢 𝘩𝘪𝘨𝘩𝘭𝘺 𝘱𝘳𝘰𝘮𝘪𝘴𝘪𝘯𝘨 𝘧𝘪𝘳𝘴𝘵-𝘪𝘯-𝘤𝘭𝘢𝘴𝘴 𝘥𝘳𝘶𝘨 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘵𝘰 𝘣𝘦𝘤𝘰𝘮𝘦 𝘢 ”𝘱𝘪𝘱𝘦𝘭𝘪𝘯𝘦 𝘪𝘯 𝘢 𝘱𝘳𝘰𝘥𝘶𝘤𝘵”. 𝘛𝘩𝘪𝘴 𝘧𝘪𝘯𝘢𝘯𝘤𝘪𝘯𝘨 𝘸𝘪𝘭𝘭 𝘦𝘯𝘢𝘣𝘭𝘦 𝘚𝘵𝘦𝘱 𝘗𝘩𝘢𝘳𝘮𝘢 𝘵𝘰 𝘤𝘰𝘮𝘱𝘭𝘦𝘵𝘦 𝘵𝘩𝘦 𝘰𝘯𝘨𝘰𝘪𝘯𝘨 𝘱𝘩𝘢𝘴𝘦 1 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘢𝘯𝘥 𝘧𝘶𝘳𝘵𝘩𝘦𝘳 𝘢𝘴𝘴𝘦𝘴𝘴 𝘵𝘩𝘦 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺 𝘰𝘧 𝘋𝘦𝘯𝘤𝘢𝘵𝘪𝘴𝘵𝘢𝘵 𝘪𝘯 𝘱𝘩𝘢𝘴𝘦 2 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭𝘴.”   👏 Congratulations to the Step Pharma team and all co-investors for this major step forward!   #Biotech #Innovation #Oncology #VentureCapital #InnoBio2

◾ Biotech Funding Highlights — September 2025 ➡️ September was another strong month for biotech financing, with $2.4B raised publicly and major oncology, inflammation, and autoimmune plays leading the way. ➡️ Top Public Raises: - uniQure – $345M | Gene therapy, CNS disorders - Dianthus Therapeutics, Inc. Therapeutics – $288M | Complement-mediated diseases - Mineralys Therapeutics, Inc. Therapeutics – $287.5M | Cardiovascular & hypertension ➡️ Top Private Rounds: - Odyssey Therapeutics Therapeutics – $213M (Series D) | Immunology & oncology - Crystalys Therapeutics Therapeutics – $205M (Series A) | Gout & inflammation - Treeline Biosciences – $200M (Series A) | Precision oncology ➡️ Ecosystem Moves: - Sanofi Ventures adds $625M to back biotech & digital health innovation. - T.Rx Capital launches with $77.5M to fund next-gen “techbio” startups. ➡️ Trends: Public financings once again outpaced private rounds. Investment clustered in oncology, inflammatory, autoimmune, and cardiovascular programs.

I am thrilled to announce several critical milestones for Immuto: an oversubscribed, $8M fundraise, the realization of our target discovery and drug development platform, and an exciting collaboration with our valued colleagues at Daiichi Sankyo US. We're pleased to have this announcement covered by Boston Business Journal (https://lnkd.in/eCewZ-DP) and FirstWord Pharma (https://lnkd.in/eMENUXCz) Stepping into this next chapter for Immuto Scientific is about doing drug discovery differently. Armed with support from our visionary investors, we are leveraging our AI-enabled structural surfaceomics platform to find the hidden conformations of surface proteins that exist only in disease. By targeting these unique structures, we can develop therapies with unmatched precision. Additionally, working alongside our colleagues at Daiichi Sankyo US, we’re building strong momentum for what’s ahead. So proud to be a member of this team and I’m so excited for everyone to see what we do next.

What if targets were defined by structure, not just expression? That’s the door we’re opening: disease-specific conformations that legacy target ID couldn’t detect. At Immuto Scientific, we’re building a next-gen protein-folding AI grounded in high-resolution structural proteomics to infer in-cell conformational states. It powers our structural surfaceomics platform and enables rational design of antibodies against structural, disease-specific epitopes—targets that simply weren’t visible before. We’re now putting that engine to work with Daiichi Sankyo US in a discovery collaboration to identify cancer-specific surface targets and develop antibodies against them. Grateful to our team and investors for making this possible. #AIinBiotech #ProteinFolding #AntibodyDiscovery #DrugDiscovery

Exciting news from the team at Immuto Scientific! We just closed an $8M financing round and launched a drug discovery collaboration with Daiichi Sankyo US. At Immuto, we’re tackling one of the toughest challenges in drug discovery — finding truly novel, disease-specific targets. Using our AI-enabled structural surfaceomics platform, we uncover hidden protein structures that open the door to new therapies with greater precision and selectivity. With this support, we’re advancing our oncology pipeline, expanding into immunology and inflammation, and most importantly — working to bring life-changing therapies to patients. An exciting future path lies ahead as we push the boundaries of what’s possible in target discovery and drug development. Grateful to our amazing team, partners, and investors who share this vision. #DrugDiscovery #Oncology #Biotech #Immunology #AIinBiotech #ADCs #CancerResearch #Innovation #Startups #LifeChangingTherapies

Celaid Therapeutics Raises $7.2M in Series B First Close to Advance HSC Expansion Platform Tokyo, Japan – Celaid Therapeutics Inc., a biotech company developing selective ex vivo hematopoietic stem cell (HSC) expansion technologies, has raised USD 7.2 million in the first close of its Series B round. Investors included venture capital firms and the Japan Agency for Medical Research and Development (AMED). The funds will be used to advance Celaid’s lead pipeline program, CLD-001, a novel ex vivo-expanded HSC therapy targeting severe pediatric non-malignant diseases, and to expand global collaborations with pharma and biotech partners leveraging its proprietary HSC expansion platform. A spinout from the University of Tokyo and University of Tsukuba, Celaid Therapeutics is pioneering safe, efficient human HSC expansion to enable next-generation cell and gene therapies for hematologic and genetic disorders, as well as angiogenesis for ischemic diseases. Including grants and subsidies, Celaid’s total funding now exceeds USD 17.14 million. #CelaidTherapeutics #Biotech #StemCells #HSCExpansion #CellTherapy #GeneTherapy #LifeSciences #JapanBiotech #AMED #UniversityOfTokyo #SeriesBFunding #HealthcareInnovation #PediatricDiseases #RegenerativeMedicine #StartupNews #MedTech #BioInnovation

Sanofi Ventures, which now has $1.4 billion in total assets, will focus its investment efforts on early players working in immunology, rare diseases, neurology and vaccines. #venturecapital #rarediseases #biospace https://hubs.li/Q03KMSGf0

Investor Matt Bettonville joins us to explore a bold new frontier in cancer care—where software can outperform pharmaceuticals. Alongside Reed Jobs at Yosemite, Matt is backing digital health tools that have shown survival outcomes rivaling, and in some cases surpassing, traditional cancer drugs. Yosemite’s hybrid model of venture investing and grantmaking is designed to fast-track innovation and ensure it reaches the people who need it most. We dive into:  📊 How digital interventions are reshaping survival curves  💸 The economics of drug development vs. digital therapeutics  🧬 Synthetic control arms and the future of clinical trials  🔍 Early detection tech—from liquid biopsies to at-home diagnostics  🌐 Why global leadership in healthcare innovation is up for grabs Listen here:  Apple: https://lnkd.in/gRkQM9aJ Spotify: https://lnkd.in/gy-C_fBD #DigitalTherapeutics #CancerInnovation #YosemiteFund #NextGenCures #EndCancer #HealthTech #TheHeartOfHealthcare